Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-04-25 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2018年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (438 characters) indicating that the company's 2018 first quarter report has been approved and is available on a regulatory website. It does not contain the actual financial data or the full report itself, but rather directs investors to where the full report can be found. According to the 'MENU VS MEAL' rule, such a brief notice that a report is published elsewhere is classified as a Report Publication Announcement (RPA).
2018-04-25 Chinese
中信证券股份有限公司对《深圳华大基因股份有限公司2017年度内部控制评价报告》的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from CITIC Securities on the 2017 internal control evaluation report of Shenzhen BGI Genomics Co., Ltd. It discusses the scope, standards, and conclusions of the internal control evaluation, including the absence of major deficiencies. The document is a standalone audit-related opinion on internal controls, not the full annual report or the internal control report itself. It is not a report publication announcement as it contains substantive content and detailed evaluation. This fits the definition of an Audit Report / Information (AR), which includes audit reports and internal control evaluation results. FY 2017
2018-04-19 Chinese
2017年度独立董事述职报告（蒋昌建）
Board/Management Information Classification · 95% confidence The document is titled '2017 年度独立董事述职报告' which translates to '2017 Annual Independent Director's Work Report'. It details the independent director's activities, attendance at board meetings, opinions on various company matters, committee work, investigations, investor protection efforts, and training during the year 2017. The content is a detailed report on the independent director's duties and performance rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on management/board activities. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document length is 3284 characters, which is substantive for such a report. Hence, the classification is MANG with high confidence.
2018-04-19 Chinese
独立董事关于第一届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the 19th meeting of the first board of directors of Shenzhen BGI Genomics Co., Ltd. It covers topics such as profit distribution plans, audit firm reappointment, use of raised funds, internal control evaluation, related party transactions, asset impairment, accounting policy changes, credit facilities, and cash management. The document references compliance with regulatory rules and company bylaws, and it is dated April 20, 2018. The content is a formal opinion report by independent directors on board meeting matters, not a full annual report or audit report itself. It is a governance-related document providing independent oversight opinions on board decisions and company practices. Therefore, it fits best under Board/Management Information (MANG), which includes announcements related to board activities and management decisions.
2018-04-19 Chinese
关于召开2017年年度股东大会的通知公告
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, agenda items to be voted on (including the 2017 annual report and related financial reports), voting procedures, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather serves as an official announcement and invitation to shareholders to attend and vote at the AGM. The presence of agenda items related to the annual report and financial decisions confirms it is an AGM notice. The document length is about 5,398 characters, which is consistent with a detailed AGM notice rather than the full annual report. Therefore, the appropriate classification is AGM Information (AGM-R).
2018-04-19 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle own funds for cash management, specifically investing in low-risk financial products. It details the board meeting resolutions, investment purpose, risk control measures, and approvals by the board, independent directors, and supervisory board. There are no financial statements or detailed financial data presented, nor is this a report of financial results or an audit. The document is a formal disclosure about a financing or capital management activity, specifically the use of idle funds for cash management. This fits best under the category of Capital/Financing Update (CAP). The document length is about 2583 characters, which is typical for an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2018-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.